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Background/aim: Primary hyperparathyroidism (PHPT) is a disease that is diagnosed more frequently and generally in the asymptomatic
period, with widely available biochemical tests. Evidence suggesting an association between PHPT and malignancy risk is increasing.
Clarification of this association will be useful in PHPT for malignancy screening and management of patients with PHPT. In this study,
we aimed to investigate the frequency of cancer in PHPT patients.
Materials and methods: A total of 775 PHPT patients were included in the retrospective study. Demographic, clinical and laboratory
data of the patients were evaluated retrospectively.
Results: Malignancy was detected in 128 (16.50%) of 775 PHPT patients (female/male: 625/150). The mean age at diagnosis of PHPT
was 57.99 ± 10.86 years, and the mean age at diagnosis of malignancy was 57.46 ± 11.17 years. Of the 128 patients with malignancy, 53
(41.40%) were diagnosed in the same year as PHPT. In terms of malignancy types, 51 (6.50%) of 775 PHPT patients had thyroid cancer.
Thyroid cancer was followed by breast cancer (2.30%) and stomach cancer (1%) in order of frequency.
Conclusion: We think that PHPT patients should be examined more carefully in terms of cancer risk, especially thyroid cancer. More
comprehensive studies are needed to clarify the relationship between PHPT and cancer.
Key words: Primary hyperparathyroidism, cancer, thyroid cancer

1. Introduction
Primary hyperparathyroidism (PHPT) is a disease
characterized by hypercalcaemia and elevated or
inappropriately normal serum level of parathyroid
hormone (PTH) due to parathyroid adenoma, hyperplasia
or rarely cancer. As biochemical tests are widely available,
PHPT has become a disease that is diagnosed more
frequently and generally in the asymptomatic period today.
PHPT is a relatively common endocrine disease with an
incidence of up to 1 in 1000 patients. PHPT can be seen
at all ages, but it is most common in the sixth decade of
life; women are affected three times more often than men
[1–2]. Half of all patients with PHPT are postmenopausal
women [3]. Its treatment requires surgical resection of the
related parathyroid gland or glands.
Increasing incidence of PHPT and good prognosis
have raised concerns about many different types of cancer
that occur during the follow-up of these patients. In
addition, PHPT can occur in patients who are followed for
any cancer. There are studies reporting that many types of
cancer such as breast, kidney, colon, skin, pancreas, lung,

hematopoietic (especially multiple myeloma), pituitary,
thymus, adrenal and thyroid are more common in patients
with PHPT than in the general population [4–7]. In terms
of the frequency of individual cancer types in PHPT
patients, it is seen that there are more studies showing that
the frequency of thyroid cancer has increased in those
patients [8–10].
Evidence suggesting an association between PHPT
and malignancy risk is increasing. The clarification
of this association will provide useful information for
malignancy screening in patients with PHPT and longterm management of those patients. In this study, we aimed
to investigate the frequency of cancer in PHPT patients.
2. Materials and methods
A total of 775 patients who were followed-up with the
diagnosis of PHPT between 2006 and 2019 were included
in this retrospective study. Necmettin Erbakan University
Meram Medical School Ethics Committee approved the
study. PHPT complications such as osteoporosis and
nephrolithiasis, the demographic, clinical, laboratory,
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radiological and pathological data of the patients were
documented from the hospital’s electronic registry. The
presence of an accompanying malignancy, ages at the time
of diagnosis of PHPT and malignancy were questioned.
2.1. Statistical analysis
Statistical analyses were performed using the SPSS 22.0
(Statistical Package for Social Sciences, IBM Corp.,
Armonk, NY, USA) program. Continuous variables were
given as mean ± standard deviation if the distribution
was normal and as median (minimum-maximum) if
the distribution was not normal. In the comparison of
independent group differences, the significance test of the
difference between the two means (independent samples
t test) was used when the parametric test assumptions are
provided. The Mann–Whitney U test was used to compare
the independent group differences when the parametric
test assumptions were not provided. For differences, p <
0.05 value was considered statistically significant.
3. Results
The data of 775 patients with PHPT were analyzed in this
study. 625 (80.6%) of the 775 patients were female, and
150 (19.4%) patients were male. 128 (16.5%) of 775 PHPT
patients were found to have a diagnosis of malignancy. The
mean age of the study population was 57.99 ± 10.86 years
at the time of the diagnosis of the PHPT and 57.46 ± 11.17
years at the time of the diagnosis of the accompanying
malignancy. The median follow-up was 5 (1–13) years for
PHPT and 5 (1–14) years for accompanying malignancy.
Parathyroid adenoma could be localized in 74.5%
(577/775) of patients and based on ultrasonography,
the parathyroid adenomas were located on the right
inferior in 46.1% of patients, left inferior in 41.0% of
patients, right superior in 5.0% of patients, left superior
in 4.8% of patients and medistinal in 1.5% of patients.
Laboratory evaluation showed that the median level of
serum calcium (Ca) was 11.20 (10.00–15.80) mg/dL,
albumin-corrected Ca was 11.13 (9.36–16.80) mg/dL,
PTH was 173 (68 –1604) pg/mL, albumin was 4.3 (2.5–
5.5) g/dL, phosphorus (P) was 2.7 (0.9–6.2) mg/dL. The
median 24-h urinary Ca excretion was 310 (100–1568)
mg/day. In females, serum Ca was 11.00 (10.00–15.80)
mg/dL, albumin-corrected Ca was 11.05 (10.00–16.80)
mg/dL, P was 2.72 (1.10V 5.60) mg/dL, albumin was
4.3 (3.2–5.2) g/dL and 24-h urinary Ca excretion was
331 (100–1568) mg/day (reference range < 250 mg/day),
while, in males, serum Ca was 11.61 (10.00–15.40) mg/dL,
albumin-corrected Ca was 11.44 (10.00–15.77) mg/dL, P
was 2.50 (0.90–6.20) mg/dL, albumin was 4.2 (2.5–5.5) g/
dL and 24-hour urinary Ca excretion was 409 (101–956)
mg/day (reference range < 300 mg/day). According
to the dual-energy X-ray absorptiometry (DEXA) and
urinary ultrasonography results, 32.9% of patients
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had osteoporosis and 17.1% had nephrolithiasis (Table
1). Frequency of nephrolithiasis was significantly higher in
men than in women (31.6% in men and 13.4% in women,
p < 0.001). There was no difference between men and
women in terms of the frequency of osteoporosis (25.8%
in men and 34.1% in women, p = 0.415).
A total of 128 (16.5%) of 775 PHPT patients were
found to have a diagnosis of malignancy. The frequency
of malignancy in PHPT patients was 29/150 (19.3%) in
men and 99/625 (15.8%) in women, but this difference did
not reach statistical significance (p = 0.327). Of the 128
patients with malignancy, 53 (41.4%) were diagnosed in
the same year as PHPT, 33 (25.7%) were diagnosed before
PHPT, and 42 (32.8%) after PHPT. In terms of malignancy
types, 51 (6.5%) of 775 PHPT patients had thyroid cancer
(48 papillary, 2 follicular, 1 medullary), and 27 of these 51
thyroid cancer patients had the diagnosis of thyroid cancer
and PHPT simultaneously (Table 2, Figure).
Of the 775 PHPT patients, 273 had thyroid nodules.
The mean number of nodules was 1.96 ± 0.95, and 242 of
them were solid and 31 of them were cystic nodules. Of the
nodules, 31 were anechoic, 96 were hypoechoic, 127 were
isoechoic, and 19 were hyperechoic. Mean nodule size was
found as 12.44 ± 8.15 mm.
Thyroid surgery was performed in 90 patients
concurrently with PHPT surgery, 7 of these 90 patients
were subjected to thyroid surgery due to preoperative
malignant fine-needle aspiration biopsy results, and 83 due
to multinodular goiter. Postoperative final thyroidectomy
pathology results were benign in 65 patients and malignant
in 25 patients.
There was no significant difference between those with
and without malignancy in PHPT patients in terms of age,
sex, follow-up time and biochemical parameters such as
Ca, P, PTH, vitamin D, creatinine and urinary Ca level.
The age at the time of diagnosis of parathyroid adenoma
was higher in those with malignancy than those without
malignancy (p = 0.019) (Table 3).
4. Discussion
According to the results of our study, 128 (16.5%) of 775
PHPT patients were found to have an accompanying
malignancy. The most common accompanying
malignancies were determined as thyroid cancer, breast
cancer and stomach cancer (51 (6.5%), 18 (2.3%) and 8
(1.0%) of patients, respectively).
Several studies have shown that PHPT patients have
an increased risk of malignancy that persists after surgery.
The increased risk may be associated with hypercalcemia
itself. High calcium levels may increase the risk of
cancer by inducing mitotic activity. There are also some
experimental studies suggesting that PTH has a tumorpromoting effect and an apoptosis-inhibiting effect.
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Table 1. Demographic, clinical and biochemical data.
Age at diagnosis (PHPT), year, mean ± SD

57.99 ± 10.86

Age at diagnosis (malignancy), year, mean ± SD

57.46 ± 11.17

Follow-up time (PHPT), year, median (min-max)

5 (1–13)

Follow-up time (malignancy), year, median (min-max)

5 (1–14)

Sex, male, n (%)

150 (19.4)

Ca, mg / dL, median (min-max)

11.20 (10.00–15.80)

Albumin-corrected Ca (min-max)

11.13 (9.36–16.80)

P, mg / dL, median (min-max)

2.70 (0.90–6.20)

PTH, ng / L, median (min-max)

173 (68–1604)

Vitamin D, ug / L, median (min-max)

12 (3–52)

Albumin, g / dL, median (min-max)

4.3 (2.5–5.5)

ALP, U / L, median (min-max)

91 (31–934)

24-hour urine calcium, mg / day, median (min-max)

310 (100–1568)

Urinary calcium elevation (n: 488), n (%)

260 (46.7)

Nephrolithiasis (n: 384), n (%)

66 (17.1)

Osteoporosis (n: 213), n (%)

70 (32.9)

Frequency of malignancy, n (%)

128 (16.5)

All values are presented as mean value ± SD, median value (minimum–maximum) or n (%).
PHPT: primary hyperparathyroidism, Ca: calcium, P: phosphorus, PTH: parathormon, ALP:
alkaline phosphatase.
Table 2. Cancer types seen in PHPT patients (n: 775).
n

%

n

%

All types of cancer

128

16.5

Thyroid cancer

51

6.5

Squamous cell skin cancer

3

0.4

Colon cancer

3

0.4

Breast cancer

18

2.3

Renal cell cancer

3

0.4

Stomach cancer
Polisitemia vera

8

1

Cervical cancer

2

0.3

7

0.9

Adenocarcinoma of unknown primary origin

2

0.3

Basal cell skin cancer

6

0.8

Esophageal cancer

2

0.3

Endometrial cancer

4

0.5

Others

15

11.7

Prostate cancer

4

0.5

However, the long-term persistence of the postoperative
cancer risk has reduced the likelihood of biochemical
irregularities that contribute to the risk of cancer and
focused on other likely mechanisms. Vitamin D inhibits
angiogenesis and invasiveness, induces apoptosis, cell
cycle arrest and differentiation, thus, exhibiting an antitumor effect, and vitamin D receptors are present in many
different cells. Defects in the vitamin D receptor alleles
cause a genetic predisposition. This genetic predisposition
may cause impairment in the regulation of the functions of
the parathyroid glands, as well as impaired apoptosis and
an increase in preneoplastic lesions [5,11].

According to the GLOBOCAN 2018 data, in both
sexes combined, lung cancer is the most commonly
diagnosed cancer (11.6% of the total cases), closely
followed by female breast cancer (11.6%), prostate cancer
(7.1%), and colorectal cancer (6.1%) [12]. In 2018, the
incidence of all cancers in our country was determined as
225.1 per 100.000 persons and lung cancer (16.5%), breast
cancer (10.6%), colorectal cancer (9.5%), prostate cancer
(8.2%), thyroid cancer (6.2%) and stomach cancer (5.0%)
constitute the first 6 types of cancer in order of frequency
[12]. In our study, the rate of malignancy in PHPT patients
was found to be 16.5%, and it was found to be at a higher
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Thyroid cancer
Breast cancer
Stomach cancer
Polisitemia vera
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Figure. Cancer types seen in PHPT patients.
Table 3. Comparison of demographic and laboratory parameters of PHPT patients with and without
accompanying malignancies.
With malignancy
(n=128)

Without malignancy
(n=647)

p

Age, years

63.02 ± 11.43

59.62 ± 13.30

0.067

Sex (female /male), n

99/29

526/121

0.301

Age at diagnosis, years

57.99 ± 10.86

55.14 ± 12.89

0.019

Follow up time (years)

5.09 ± 3.53

4.58 ± 3.51

0.132

Ca, mg / dL

11.29 ± 0.82

11.36 ± 0.81

0.378

Albumin-corrected Ca, mg / dL

11.13 ± 0.92

11.12 ± 0.88

0.871

P, mg / dL

2.76 ± 0.66

2.72 ± 0.63

0.516

PTH, ng / L

239.2 ± 229.53

218.3 ± 171.84

0.247

Vitamin D, ug / L

15.57 ± 10.72

14.84 ± 9,65

0.494

Creatinin, mg / dL

0.76 ± 0.27

0.77 ± 0.26

0.769

24-hour urine calcium, mg / day

322 ± 176

352 ± 180

0.171

All values are presented as mean value ± SD, median value (minimum–maximum) or n (%). Ca: calcium,
P: phosphorus, PTH: parathormon.

frequency than the general population. In addition, unlike
the general population, thyroid cancer was found to be
the most common accompanying malignancy in PHPT
patients.
A study including 9782 operated patients from Sweden
showed an increased risk of cancer in both sexes, with risk
persisting for more than 15 years after surgical correction
of PHPT. The authors reported that breast cancer accounts
for a quarter of all cancer cases in women, with an increased
risk of colon, kidney, and squamous cell cancer in both
sexes. An interesting result found in that study is that the
risk of endocrine and pancreatic cancer is increased in the
small subgroup operated before the age of 40 [5]. In our
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study, breast cancer was seen in 2.3% of PHPT patients
and ranked second after thyroid cancer among cancers
cases seen in PHPT patients.
In a study involving 3039 PHPT patients, Ghosh et al.
found an increased incidence of cancer cases in patients
who were conservatively managed or surgically treated,
and reported that the most common types of cancer were
colon, breast, lung and skin (non-melanoma) cancers. The
authors also reported that surgery delays the occurrence
of cancer but does not reduce it [7]. In our study, both
surgically and conservatively managed patients were
included, and separate evaluation has not been made
for those who underwent surgical treatment and were
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followed up conservatively. However, in our study, unlike
Ghosh et al., the most common cancers were those of
thyroid, breast and stomach.
In the literature, the prevalence of thyroid carcinoma
with concomitant PHPT ranges from 1% to 36 [13–20]. In
their study investigating the prevalence of thyroid disease
and thyroid malignancy in patients who underwent
surgical treatment for PHPT, Çuhaci et al. found the
thyroid malignancy prevalence as 20.8% (all patients with
malignant disease had papillary thyroid cancer) [13].
In a similar study, Preda et al. reported the incidence of
thyroid cancer as 13.6% in PHPT patients who underwent
surgery [21]. In our study, the frequency of thyroid cancer
in PHPT patients was found to be 6.5%, but, unlike those
studies, we did not separately evaluate PHPT patients who
underwent surgical treatment.
Previous studies have investigated several predisposing
factors for papillary thyroid cancer in PHPT patients,
such as the tumor promoting effect of PTH [22], the
goitrogenic effect and increased mitotic activity induced
by hypercalcemia [5,23,24] and neck irradiation [5,24,25].
A presumed role for PTH excess in triggering the onset
of papillary thyroid cancer remains controversial [26]. In
the study of Preda et al., although PTH levels were much
higher in patients with secondary hyperparathyroidism,
the similar incidence of papillary thyroid cancer in patients
with secondary hyperparathyroidism and PHPT is contrary
to the opinion that high PTH level may trigger papillary
thyroid cancer [21]. Pickard et al. found that cancer risk
in patients with secondary hyperparathyroidism was

insignificant, and, in the light of this data, they suggested
that PTH itself is not the cause of malignancies [27].
The limitations of our study are its small sample size,
single center and retrospective design.
Our study confirms the earlier findings of a connection
between PHPT and increased risk of malignancy. It is
not clear whether this increased risk is due to genetic
predisposition to tumor development or whether it is a
physiological associative effect, intrinsic or environmental.
For all these reasons, PHPT patients should be examined
and monitored more carefully for all cancers, especially
thyroid cancer. More comprehensive studies are needed to
clarify the relationship between PHPT and cancer.
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